A
Alcista
Alcista · 25%NPCE
$19.11
Precio del escenario
$13.140
+0.091 (+0.69%)Al cierre
Loading chart…
- Máximo
- 13.430
- Apertura
- 13.050
- Precio medio ponderado por volumen
- 13.16
- Volumen
- 97.95K
- Capitalización
- 201.38M
- Mínimo
- 12.920
- Importe
- 1.29M
- EV/EBITDA, TTM
- -20.41
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.
Análisis de IA of Neuropace Inc (NPCE)
MantenerNeuropace Inc is not a strong buy right now due to its current price of $12.24, which is below the analyst price targets of $18 and $22. The RSI is at 32.355, indicating the stock is oversold, but the forward P/E ratio is extremely high at 158.73, suggesting overvaluation. The recent FDA denial for the RNS system expansion poses a significant risk, as it impacts the company's primary revenue source.
Métricas de valoración
El PER previsto actual de Neuropace Inc (NPCE) es 158.73, frente a su media de 5 años de -2.65.
Escenarios de precio de Alphio AI para NPCE
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NPCE en cartera
Cronología de eventos
Noticias
6.009-18CNBCMajor Wall Street Rating Updates Overview
9.007-29seekingalphaNeuroPace Faces FDA Denial for RNS System Expansion
9.007-28NewsfilterNeuroPace FDA Review Update: PMA Supplement Not Approvable
- 1.005-29Newsfilter
NeuroPace to Showcase New Technologies at ASSFN Meeting
- 3.505-29Newsfilter
NeuroPace Receives FDA Approval for First AI Tool
Preguntas frecuentes sobre NPCE, respondidas por Alphio AI
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Neuropace Inc is not a strong buy right now due to its current price of $12.24, which is below the analyst price targets of $18 and $22. The RSI is at 32.355, indicating the stock is oversold, but the forward P/E ratio is extremely high at 158.73, suggesting overvaluation. The recent FDA denial for the RNS system expansion poses a significant risk, as it impacts the company's primary revenue source.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.